Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6129428 | Clinical Microbiology and Infection | 2015 | 25 Pages |
Abstract
The increasing prevalence of colistin resistance (ColR) Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (Kp) is a matter of concern because of its unfavourable impact on mortality of KPC-Kp bloodstream infections (BSI) and the shortage of alternative therapeutic options. A matched case-control-control analysis was conducted. The primary study end point was to assess risk factors for ColR KPC-Kp BSI. The secondary end point was to describe mortality and clinical characteristics of these infections. To assess risk factors for ColR, 142 patients with ColR KPC-Kp BSI were compared to two controls groups: 284 controls without infections caused by KPC-Kp (control group A) and 284 controls with colistin-susceptible (ColS) KPC-Kp BSI (control group B). In the first multivariate analysis (cases vs. group A), previous colistin therapy, previous KPC-Kp colonization, â¥3 previous hospitalizations, Charlson score â¥3 and neutropenia were found to be associated with the development of ColR KPC-Kp BSI. In the second multivariate analysis (cases vs. group B), only previous colistin therapy, previous KPC-Kp colonization and Charlson score â¥3 were associated with ColR. Overall, ColR among KPC-Kp blood isolates increased more than threefold during the 4.5-year study period, and 30-day mortality of ColR KPC-Kp BSI was as high as 51%. Strict rules for the use of colistin are mandatory to staunch the dissemination of ColR in KPC-Kp-endemic hospitals.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
D.R. Giacobbe, V. Del Bono, E.M. Trecarichi, F.G. De Rosa, M. Giannella, M. Bassetti, A. Bartoloni, A.R. Losito, S. Corcione, M. Bartoletti, E. Mantengoli, C. Saffioti, N. Pagani, S. Tedeschi, T. Spanu, G.M. Rossolini, A. Marchese, S. Ambretti,